Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berotralstat for Prevention of HAE Attacks (APeX-2)
NCT03485911Phase 3Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc.. Started Feb 2018; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT03485911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485911.